Bioptimus, the leader in AI models for biology, today announced a major leap forward with the unveiling of M-Optimus, the first model that combines multiple biological modalities, designed to simulate ...

Three recently published studies by Medical University of South Carolina researchers each adopted a unique approach to ...

Gene editing has rapidly evolved into a transformative class of technologies that allow scientists to precisely insert, ...

Memorial Sloan Kettering Cancer Center researchers continued to make strides against cancer in 2025. Learn about some of ...

In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

Q4 2025 showcased the industry’s pivot toward precise biology, localised delivery, and earlier intervention – with multiple ...

Multi-agency response team provides updates on One Health approach to New World screwworm; biosecurity and sterile fly ...

In this article, we examine ongoing challenges shaping target-based drug discovery and highlight how new technologies and ...

Hematologists and oncologists from UC San Francisco shared research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology at the American Society of ...

Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day December 10, 2025 1:00 PM ...

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...

Detailed price information for Senti Biosciences Inc (SNTI-Q) from The Globe and Mail including charting and trades.